false 0001074871 0001074871 2024-08-22 2024-08-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 22, 2024

 

MODULAR MEDICAL, INC.
(Exact name of registrant as specified in its charter)

 

Nevada   001-41277   87-0620495
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

10740 Thornmint Road, San Diego, California   92127
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 800-3500

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock   MODD   The Nasdaq Stock Market LLC 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously reported, on October 2, 2023, the Board of Directors of Modular Medical, Inc. (the “Company”) approved the Modular Medical, Inc. Two-Part FDA Submission and Clearance Milestone Bonus Program (the “Bonus Program”) to motivate and incentivize the Company’s employees. Under the terms of the Bonus Program, certain of the Company’s employees, including the Company’s executive officers, would receive a bonus in the event that the Company achieved the following milestones for its initial insulin pump product (the “MODD-1”): (i) completion of all verification and validation testing by December 31, 2023 and 510(k) premarket submission to the U.S. Food and Drug Administration (the “FDA”) by January 31, 2024 (“Milestone 1”) and (ii) receipt of notification of FDA clearance of the MODD-1 (the “Notification”) by August 1, 2024 (“Milestone 2”). The following summary is qualified in its entirety by the provisions of the Bonus Program, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 5, 2023.

 

Under the Bonus Program, the Company granted options to purchase shares of the Company’s common stock to its executive officers (the “Executive Bonus Program Options”), as set forth in the table below.

 

Name  Position  Milestone 1
Options
   Milestone 2
Options
 
James Besser  Chief Executive Officer   135,136    - 
Paul DiPerna  Chairman, President, Chief Financial Officer and Treasurer   90,091    45,046 
Kevin Schmid  Chief Operating Officer   37,538    18,769 

 

The Executive Bonus Program Options were granted on October 2, 2023 (the “Grant Date”) under the Company’s Amended 2017 Equity Incentive Plan (the “2017 Plan”), had an exercise price of $1.11 per share (the closing price of the Company’s common stock on the Grant Date) and a term of 10 years. The Milestone 1 Options vested in full on January 19, 2024. Pursuant to the terms of the Bonus Program, the Milestone 2 Options were canceled on August 2, 2024, as the Company did not receive the Notification by August 1, 2024.

 

On August 22, 2024, the Company’s Board of Directors granted new options to certain executive officers, as set forth in the table below.

 

Name  Position  Options 
Paul DiPerna  Chairman, President, Chief Financial Officer and Treasurer   58,560 
Kevin Schmid  Chief Operating Officer   24,400 

 

Such options were granted on August 22, 2024 (the “New Grant Date”) under the 2017 Plan, have an exercise price of $1.71 per share (the closing price of the Company’s common stock on the New Grant Date) and a term of 10 years. The options will vest as to all of the shares subject to the option if the Company receives the Notification on or before December 31, 2024. If the Company does not receive the Notification on or before that date, the options will not vest as to any of the shares and will terminate on January 1, 2025. 

 

In addition, the Company’s Board of Directors approved new options for certain non-executive employees of the Company to purchase an aggregate of 256,338 shares of the Company’s common stock. Such options will vest as to all of the shares subject to the option if the Company receives the Notification on or before December 31, 2024. If the Company does not receive the Notification on or before that date, the options will not vest as to any of the shares and will terminate on January 1, 2025.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Indicates a management contract or compensatory plan or arrangement.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MODULAR MEDICAL, INC.
     
Date: August 27, 2024 By: /s/ James E. Besser
    James E. Besser
    Chief Executive Officer

 

 

2

 

 

 

v3.24.2.u1
Cover
Aug. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 22, 2024
Entity File Number 001-41277
Entity Registrant Name MODULAR MEDICAL, INC.
Entity Central Index Key 0001074871
Entity Tax Identification Number 87-0620495
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 10740 Thornmint Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92127
City Area Code 858
Local Phone Number 800-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol MODD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

Modular Medical (NASDAQ:MODD)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 Modular Medical 차트를 더 보려면 여기를 클릭.
Modular Medical (NASDAQ:MODD)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 Modular Medical 차트를 더 보려면 여기를 클릭.